[HTML][HTML] Process data of allogeneic ex vivo-expanded ABCB5+ mesenchymal stromal cells for human use: off-the-shelf GMP-manufactured donor-independent …
S Ballikaya, S Sadeghi, E Niebergall-Roth… - Stem Cell Research & …, 2020 - Springer
S Ballikaya, S Sadeghi, E Niebergall-Roth, L Nimtz, J Frindert, A Norrick, N Stemler, N Bauer…
Stem Cell Research & Therapy, 2020•SpringerBackground Human dermal mesenchymal stromal cells (MSCs) expressing the ATP-binding
cassette (ABC) efflux transporter ABCB5 represent an easily accessible MSC population
that, based on preclinical and first-in-human data, holds significant promise to treat a broad
spectrum of conditions associated not only with skin-related but also systemic inflammatory
and/or degenerative processes. Methods We have developed a validated Good
Manufacturing Practice-compliant expansion and manufacturing process by which ABCB5+ …
cassette (ABC) efflux transporter ABCB5 represent an easily accessible MSC population
that, based on preclinical and first-in-human data, holds significant promise to treat a broad
spectrum of conditions associated not only with skin-related but also systemic inflammatory
and/or degenerative processes. Methods We have developed a validated Good
Manufacturing Practice-compliant expansion and manufacturing process by which ABCB5+ …
Background
Human dermal mesenchymal stromal cells (MSCs) expressing the ATP-binding cassette (ABC) efflux transporter ABCB5 represent an easily accessible MSC population that, based on preclinical and first-in-human data, holds significant promise to treat a broad spectrum of conditions associated not only with skin-related but also systemic inflammatory and/or degenerative processes.
Methods
We have developed a validated Good Manufacturing Practice-compliant expansion and manufacturing process by which ABCB5+ MSCs derived from surgical discard skin tissues are processed to an advanced-therapy medicinal product (ATMP) for clinical use. Enrichment for ABCB5+ MSCs is achieved in a three-step process involving plastic adherence selection, expansion in a highly efficient MSC-selecting medium, and immunomagnetic isolation of the ABCB5+ cells from the mixed culture.
Results
Product Quality Review data covering 324 cell expansions, 728 ABCB5+ MSC isolations, 66 ABCB5+ MSC batches, and 85 final drug products reveal high process robustness and reproducible, reliable quality of the manufactured cell therapy product.
Conclusion
We have successfully established an expansion and manufacturing process that enables the generation of homogenous ABCB5+ MSC populations of proven biological activity manufactured as a standardized, donor-independent, highly pure, and highly functional off-the-shelf available ATMP, which is currently tested in multiple clinical trials.
Springer
